1 / 15

Multiple Sclerosis

Multiple Sclerosis. Developed by Dr. June Carroll, Ms. Shawna Morrison, Dr. Judith Allanson Last updated April 2015. Disclaimer.

petrus
Télécharger la présentation

Multiple Sclerosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multiple Sclerosis Developed by Dr. June Carroll, Ms. Shawna Morrison, Dr. Judith Allanson Last updated April 2015

  2. Disclaimer • This presentation is for educational purposes only and should not be used as a substitute for clinical judgement. GEC-KO aims to aid the practicing clinician by providing informed opinions regarding genetic services that have been developed in a rigorous and evidence-based manner. Physicians must use their own clinical judgement in addition to published articles and the information presented herein. GEC-KO assumes no responsibility or liability resulting from the use of information contained herein.

  3. Objectives • Following this session the learner will be able to: • Refer to their local genetics centre and/or order genetic testing appropriately for multiple sclerosis (MS) • Discuss and address patient concerns regarding MS • Find high quality genomics educational resources appropriate for primary care

  4. Case 82 d.78 • Mary, 46yo female • Diagnosed with MS at age 45 • Concerned about the risks for her siblings and her daughter A&W Colon CA dx 75 46 44 40 Mary MS Dx 45 A&W A&W 10 A&W

  5. What is multiple sclerosis? • Multiple sclerosis (MS) is a demyelinating condition of the central nervous system (CNS), characterized by inflammation and axonal degeneration • Most common course of disease is marked by relapse into symptoms followed by periods of remission • Onset typically between age 20 and 40 years but can appear at any age • 1/500 Canadians affected • Female 2-3x > male • Symptoms • Numbness or tingling • Visual disturbances • Difficulty walking • Fatigue

  6. What are the risks for relatives to develop multiple sclerosis? • First degree relatives of individuals with MS have a 3-5% chance to develop MS in their lifetime (15-25x higher than population prevalence) • Risk to relatives increases with the number of affected family members and the closeness of relationship between them • Risk for the monozygotic twin of an individual with MS approaches 30%

  7. What do I need to know about the genetics of multiple sclerosis? • The HLA DRB1 gene, lying within the major histocompatibility complex, has consistently been associated with MS • Function: to distinguish self from foreign antigen • The HLA DRB1*1501 variant is found 2-3x more often in those with MS than in unaffected controls • Recently, dozens of genes with odds ratios of <1.2 have been identified which collectively contribute small effects to overall MS risk • The vast majority of these susceptibility variants have an immune-related function • Some people with MS have few or none of these susceptibility variants and conversely, most people found to carry these variants will never develop MS

  8. Is genetic testing and/or referral for genetic consultation important? • Most of the time, a diagnosis of MS is not a strong indicator to refer for genetic assessment • Discussions of recurrence risks, psychosocial needs and medication safety during child-bearing years can be initiated by primary healthcare providers or neurologists • Genetic testing is not available for diagnostic, predictive or prenatal purposes

  9. Who should be offered genetic testing and/or referral for genetic consultation? • Referral to Genetic or Metabolic specialists should be considered for individuals who: • Present at a very young age (i.e. less than 10 years) • Display a strong family history in keeping with Mendelian inheritance (dominant, recessive or X-linked) • Have MRI findings atypical for MS • Do not experience typical progression in keeping with the natural history of MS • Have a diagnosis of MS and develop atypical symptoms such as migraine or dementia which may indicate the need to rule out other diseases (e.g. inherited arteriopathy or leukoencephalopathy) Any of the above may indicate a rare form of demyelinating disease, some of which are caused by a single gene mutation

  10. Case 82 d.78 A&W Colon CA dx 75 • What risk do Mary’s first degree relatives have? 46 44 40 Mary MS Dx 45 A&W A&W 10 A&W

  11. Case 82 d.78 A&W Colon CA dx 75 • Mary’s first degree relatives have an increased risk 15-25x greater than the general population risk: 3-5% 46 44 40 Mary MS Dx 45 A&W A&W 3-5% risk for MS 10 A&W 3-5% risk for MS

  12. Pearls • First degree relatives of an affected individual have a 3-5% lifetime MS risk (15-25x greater than population risk) • Clinical genetic testing for MS is not available • Consider genetic consultation if you see a patient with numerous affected relatives or atypical symptoms/course as diagnosis may not be MS but rather an MS mimic

  13. References 1. Paty D, Ebers G. Multiple Sclerosis. Philadelphia.: FA Davis., 1997. 2. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100(22):12877-82 3. Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004; 363(9423):1773-4 4. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995; 377(6545):150-1 5. Ebers GC, Yee IM, Sadovnick AD, et al. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol 2000; 48(6):927-31 6. Dyment DA, Yee IM, Ebers GC, et al. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry 2006; 77(2):258-9 7. Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 2009; 22(3):219-25 8. Dyment DA, Herrera BM, Cader MZ, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005; 14(14):2019-26 9. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45(11):1353-60 10. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476(7359):214-9 11. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7(3):268-77 12. Aliaga ES, Barkhof F. MRI mimics of multiple sclerosis. Handb Clin Neurol 2014; 122:291-316.

More Related